Phase 2 EGFR Activating Mutation trials recruiting now

All EGFR Activating Mutation trials, every phase

Phase 2 EGFR Activating Mutation trials

• EGFR-TKIs Plus PD-1 in EGFR-Mutant Advanced NSCLC
  NCT07637448 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial
  NCT06363734 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases
  NCT05948813 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location

Common questions

What does Phase 2 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.